ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth.
Our clinically superior ADAPT® products are the only ones to have achieved nine years without calcification or degradation.
With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.
ADAPT® products are sold globally under the product names CardioCel®, CardioCel Neo®, CardioCel 3D®, and VascuCel® (product availability subject to regional regulatory approval).
Our flagship product, CardioCel®, is currently being used by surgeons in more than 135 global centres in Australia, Europe, US, Canada, Singapore, Malaysia, Hong Kong, India and the Middle East and North Africa Region.
All Admedus ADAPT® products are manufactured in, and distributed from, our state-of-the-art biomanufacturing facility which has substantial capacity to expand and includes an in-house research and development laboratory.